Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — H.C. Wainwright BioConnect 2021 Conference
14 slides from Nemaura Medical's conference presentation, Jan 12, 2021
Slide 1: Corporate Presentation, H.C. Wainwright BioConnect 2021 Conference
Corporate Presentation H.C.WAINWRIGHT & CO BIOCONNECT 2021 Conference Dr Faz Chowdhury, CEO January 11 - 14, 2021
Slide 2: Forward-Looking Statements
Forward - Looking Statements • This presentation includes forward - looking statements that are subject to many risks and uncertainties. These forward - looking statements, such as statements about Nemaura’s short - term and long - term growth strategies, can sometimes be identified by use of terms
Slide 3: Investment Highlights
Investment Highlights A World first daily wear Continuous glucose monitor Commercialized as sugarBEAT® (Class 2b CE approved medical device) and proBEAT Ρ (in USA under wellbeing category pre - PMA approval) Applicable for Pre - diabetes (diabetes prevention), Type 1 (glucose trending) and Type 2 Di
Slide 4: How it works
How it works Apply the sensor
Slide 5: How it works
How it works @ See changes as they happen Helps you understand your unique glucose trend line and lifestyle choices taken.
Slide 6: How it works: YesYouCan BEAT diabetes
How it works YesYouCan BEAT™diabetes
Slide 7: Benefits over HbA1c
Benefits over HbA1c Thesame HbAlc presented differently
Slide 8: BEAT diabetes Global program launched in the USA in December 2020
BEAT Ρ diabetes Global program L aunched in the USA in December 2020 Key Targets: 1. Prevent diabetes – target >80 million people with pre - diabetes in the USA 1. Reverse Diabetes – targeting >25 million persons in the USA 8
Slide 9: Obesity and Diabetes: Two Major Drivers of the Chronic Disease Epidemic
Obesity and Diabetes: TWO of the major drivers of the chronic disease Epidemic The added cost of managing a Type 2 diabetic person is >$6000/year. This can be avoided by preventing or reversing Type 2 Diabetes 9 Pre - Diabetics >80 million Type 2 >25 million
Slide 10: Full Program Launched December 2020 in USA
10 FULL PROGRAM LAUNCHED DECEMBER 2020 IN USA 3 CORE COMPONENTS 1. Weight loss program originally developed at the Joslin Institute – over 12 years of clinical evidence. Sustained long term weight loss achieved 2. proBEAT Ρ glucose profiling – worlds first daily - wearable glucose sensor, developed
Slide 11: Intermittent Glucose Profiling Benefits
Intermittent Glucose Profiling: B enefits 11 7 - point glucose profiles every 4 weeks. Patients received guidance for diet and exercise adjustments based on SMBG. Outcome: Significant reductions in HbA1c, weight, BMI, systolic BP, diastolic BP, and LDL Cholesterol Kempf et. al., Diabetes Technol The
Slide 12: Glucose trend and diet , exercise , and other parameters used to determine individual
12 Glucose trend and diet , exercise , and other parameters used to determine individual metabolic health . Combine with education and guidance
Slide 13: Disease prevention in place of medical treatment
Our studies reveal that over 30% of the average workforce are li 1g with chronic disease, with another ‘35% or more at risk of developing a chronic condition during their life. Disease prevention in place of medical treatment is the new paradigm, and our program is built with HBAIC CHANGE (%) oo as
Slide 14: Summary
SUMMARY 1. Total addressable market >$150 Billion 2. World first daily wearable sensor with unparalleled economics 3. Targeting prevention and Type 2 diabetes reversal with significant long term savings 4. Glucose profiling a few days a month provides a powerful cost - effective tool to facilitate m
Nemaura Medical — H.C. Wainwright BioConnect 2021 Conference on 6ix